Valuation Picture: Premium Amidst Sector Norms
The current P/E of 35.03 for Sun Pharmaceutical Industries Ltd stands approximately 4.2% above the Pharmaceuticals & Biotechnology industry average of 33.60. This premium suggests that investors are willing to pay slightly more for the stock relative to its peers, reflecting expectations of either superior earnings growth or a perception of lower risk. However, the premium is not excessive, indicating a valuation that remains broadly in line with sector norms. The market capitalisation of Rs 4,37,986.60 crore further cements its status as a large-cap stalwart within the sector.
Performance Across Timeframes: Divergent Momentum
Examining the returns over various periods reveals a complex performance profile. Over the past year, Sun Pharmaceutical Industries Ltd has delivered a 10.90% gain, significantly outperforming the Sensex’s decline of 5.32% during the same period. This outperformance underscores the stock’s resilience amid broader market challenges. However, the one-month return tells a different story, with the stock declining 4.19% while the Sensex rose 2.39%. This short-term weakness contrasts with the positive three-month return of 2.63%, which still outpaces the Sensex’s 0.54% gain. The 1-week return of 1.74% trails the Sensex’s 4.45%, suggesting recent relative underperformance despite a positive absolute move.
The 3-month and 1-year returns indicate that the stock has maintained a positive trajectory over medium to longer horizons, but the recent one-month dip raises questions about near-term pressures — is this a temporary setback or a sign of shifting fundamentals? The year-to-date return of 6.15% also contrasts with the Sensex’s negative 9.51%, reinforcing the stock’s relative strength in 2026 so far.
Moving Average Configuration: Bullish Across All Key Levels
Technically, Sun Pharmaceutical Industries Ltd is trading above all major moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day. This comprehensive positioning above short, medium, and long-term averages signals a robust upward trend and suggests sustained buying interest. The stock is currently just 4.86% below its 52-week high of Rs 1917.15, indicating proximity to recent peak levels. The two-day consecutive gain, amounting to a 1.53% rise, further supports the notion of positive momentum in the near term.
From struggle to strength! This Small Cap from Textile - Machinery is showing early turnaround signals that look promising. Position yourself now for explosive growth potential ahead!
- - Early turnaround signals
- - Explosive growth potential
- - Textile - Machinery recovery play
Relative Performance Versus Sensex: Consistent Outperformance Over Medium Term
Over the three-year and five-year horizons, Sun Pharmaceutical Industries Ltd has delivered returns of 83.98% and 173.11% respectively, vastly outperforming the Sensex’s 21.66% and 47.32% over the same periods. This long-term outperformance highlights the company’s ability to generate shareholder value beyond cyclical market movements. However, the ten-year return of 145.75% trails the Sensex’s 189.62%, reflecting a period of relative underperformance in the more distant past.
Shorter-term comparisons reveal a more mixed picture. The stock’s 1-day gain of 0.30% slightly outpaces the Sensex’s marginal decline of 0.05%, but the 1-week return of 1.74% lags behind the Sensex’s 4.45%. This suggests that while the stock remains resilient, it has not fully participated in the recent broader market rally — does this indicate a cautious stance among investors or sector-specific headwinds?
Sector Performance Context: Mixed Results Amidst Pharmaceuticals & Biotechnology
The Pharmaceuticals & Biotechnology sector has seen 35 stocks declare results recently, with 19 reporting positive outcomes, 9 flat, and 7 negative. This distribution indicates a broadly constructive environment for the sector, though not without pockets of weakness. Sun Pharmaceutical Industries Ltd appears to be navigating this landscape effectively, as evidenced by its relative outperformance over multiple timeframes and its premium valuation.
Rating Reassessment: Previously Rated Hold
MarketsMOJO had previously assigned a Hold rating to Sun Pharmaceutical Industries Ltd, with a Mojo Score of 74.0. The rating was updated on 8 June 2026, reflecting a reassessment of the company’s fundamentals and market position. The current valuation premium and the technical strength suggest a positive shift in the company’s profile — previously rated Hold, what is Sun Pharmaceutical Industries Ltd’s current rating?
Want to dive deeper on Sun Pharmaceutical Industries Ltd? There's a real-time research report diving right into the fundamentals, valuations, peer comparison, financials, technicals and much more!
- - Real-time research report
- - Complete fundamental analysis
- - Peer comparison included
Collective Data Insights: Valuation, Momentum, and Technical Strength
The data for Sun Pharmaceutical Industries Ltd paints a picture of a large-cap pharmaceutical company trading at a slight valuation premium relative to its sector. Its one-year and medium-term returns have outpaced the Sensex, though recent short-term performance has been mixed. The stock’s position above all major moving averages signals technical strength and a sustained upward trend. Sector results are broadly positive, supporting the company’s relative performance. The recent rating reassessment from Hold reflects these evolving fundamentals and market dynamics — should investors in Sun Pharmaceutical Industries Ltd hold, buy more, or reconsider?
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
